Clinical Trials
12 trialsNCT05386108 2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
NCT05270707 2025-09-24
HyperArc Registry Study
Varian, a Siemens Healthineers Company
Completed
NCT05321498 2023-09-28
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Inmune Bio, Inc.
Phase 2 Withdrawn
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT01081223 2023-06-01
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
Phase 1/2 Completed
NCT03650452 2021-02-18
ELEKTRA
Takeda
Phase 2 Completed
NCT00649207 2017-11-21
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
AbbVie
Phase 1 Completed
NCT01386580 2015-01-22
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
Phase 1/2 Completed
NCT00643890 2012-02-22
Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease
Neurologix, Inc.
Phase 2 Terminated
NCT00906516 2009-05-21
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Bradmer Pharmaceuticals Inc.
Phase 2 Unknown